SCHEMBL8286122

SCHEMBL8286122

CNCCN(C)C(=O)c1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 2/20 0.47
CCND1 P24385 2/20 0.47
ALDH1A1 P00352 4/20 0.45
CDK2 P24941 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
MMP13 P45452 1/20 0.43
LIMK2 P53671 1/20 0.42
HDAC6 Q9UBN7 3/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23417260 0.90 HDAC6 (0.46) CDK4CCND1ALDH1A1CDK2MMP13
SCHEMBL26481584 0.86 ESRRG (0.52) OPRM1OPRD1HDAC6HDAC1HDAC3
SCHEMBL1833078 0.84 OPRM1 (0.51) CDK4CCND1OPRM1OPRD1HDAC6
SCHEMBL24732320 0.81 HSD17B2 (0.59) CDK4CCND1ALDH1A1CDK2LIMK2
SCHEMBL5019024 0.81 MEN1 (0.49) HDAC6CES2CES1MEN1NPC1
SCHEMBL842996 0.81 HPGD (0.54) CDK4CCND1HDAC6HDAC8LMNA
SCHEMBL13069798 0.81 KMT2A (0.55) CDK4CCND1ALDH1A1CDK2MMP13
SCHEMBL21077963 0.80 CDK4 (0.50) CDK4CCND1ALDH1A1CDK2MMP13
SCHEMBL12237841 0.80 CDK4 (0.50) CDK4CCND1ALDH1A1CDK2MMP13
SCHEMBL11748046 0.80 CDK4 (0.50) CDK4CCND1ALDH1A1CDK2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021099793-A1 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS Infex Therapeutics Limited (GB) 2021-05-27 WO disclosed
US-20170152391-A1 COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK DIC CORPORATION (JP) 2017-06-01 US disclosed
WO-2005087726-A1 NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152391-A1 COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK CCNT1, EIF4A1, MARK1 CDK4 240/4885CCND1 212/4885ALDH1A1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.